Why the study?
Does moxonidine improve blood pressure and metabolic parameters in obese hypertensive patients compared to amlodipine?
Population
Obese hypertensive patients
Comparison
Moxonidine for 24 weeks vs Amlodipine
Design
RCT, randomised open parallel study, open
Follow-up
24 weeks
Authors
Loading...
Supports moxonidine preference in obese hypertension for metabolic gains; extends RCT evidence for central sympatholytics beyond BP control.
Does moxonidine improve blood pressure and metabolic parameters in obese hypertensive patients compared to amlodipine?
Moxonidine provides comparable blood pressure reduction to amlodipine in obese hypertensive patients while additionally improving sympathetic nervous activity, insulin resistance, and leptin levels.
Sanjuliani et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: